PTGER4 and obesity disorder: Administration of another EP4 agonist, CAY10580, reduced AT IP-10 and MIP-1α levels in high fat diet-challenged mice, suggesting systemic EP4 activation alleviates obesity-associated AT inflammation and such anti-inflammatory effects outweigh potential EP4-mediated metabolic defects (218).